JP2022504435A - イブジラストとインターフェロン－ベータとの組み合わせ、およびそれを使用する方法 - Google Patents

イブジラストとインターフェロン－ベータとの組み合わせ、およびそれを使用する方法 Download PDF

Info

Publication number
JP2022504435A
JP2022504435A JP2021518962A JP2021518962A JP2022504435A JP 2022504435 A JP2022504435 A JP 2022504435A JP 2021518962 A JP2021518962 A JP 2021518962A JP 2021518962 A JP2021518962 A JP 2021518962A JP 2022504435 A JP2022504435 A JP 2022504435A
Authority
JP
Japan
Prior art keywords
interferon
beta
ibudilast
day
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021518962A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020076809A5 (enExample
Inventor
和子 松田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicinova Inc
Original Assignee
Medicinova Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicinova Inc filed Critical Medicinova Inc
Publication of JP2022504435A publication Critical patent/JP2022504435A/ja
Publication of JPWO2020076809A5 publication Critical patent/JPWO2020076809A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2021518962A 2018-10-09 2019-10-08 イブジラストとインターフェロン－ベータとの組み合わせ、およびそれを使用する方法 Pending JP2022504435A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862743449P 2018-10-09 2018-10-09
US62/743,449 2018-10-09
PCT/US2019/055167 WO2020076809A1 (en) 2018-10-09 2019-10-08 Combination of ibudilast and interferon-beta and methods of using same

Publications (2)

Publication Number Publication Date
JP2022504435A true JP2022504435A (ja) 2022-01-13
JPWO2020076809A5 JPWO2020076809A5 (enExample) 2022-10-13

Family

ID=68343518

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021518962A Pending JP2022504435A (ja) 2018-10-09 2019-10-08 イブジラストとインターフェロン－ベータとの組み合わせ、およびそれを使用する方法

Country Status (7)

Country Link
US (1) US10946071B2 (enExample)
EP (1) EP3863628B1 (enExample)
JP (1) JP2022504435A (enExample)
CN (1) CN112770748A (enExample)
CA (1) CA3115269A1 (enExample)
ES (1) ES2973119T3 (enExample)
WO (1) WO2020076809A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3226898A1 (en) 2021-07-26 2023-02-02 Kazuko Matsuda Ibudilast for preventing eye cancer metastasis
US12042485B2 (en) 2021-10-07 2024-07-23 Medicinova, Inc. Methods of minimizing cancer metastasis

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060093578A1 (en) * 2004-11-04 2006-05-04 Kyorin Pharmaceutical Co., Ltd. Method and composition for treating multiple sclerosis
JP2010533193A (ja) * 2007-07-11 2010-10-21 メディシノバ，インコーポレーテッド イブジラストを含む進行性神経変性疾患の処置用医薬組成物
JP2012532881A (ja) * 2009-07-10 2012-12-20 サノフィ−アベンティス・ユー・エス・エルエルシー 多発性硬化症を処置するためのテリフルノミドとインターフェロンベータとの組み合わせの使用
JP2017095476A (ja) * 2010-12-07 2017-06-01 テバ ファーマシューティカル インダストリーズ リミティド 多発性硬化症患者において疲労を軽減し、機能状態を改善し、生活の質を改善するための、ラキニモド（ｌａｑｕｉｎｉｍｏｄ）の使用
JP2017132769A (ja) * 2011-02-18 2017-08-03 ザ スクリプス リサーチ インスティテュート ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化
JP2018080184A (ja) * 2006-05-24 2018-05-24 メルク セローノ ソシエテ アノニム 多発性硬化症を治療するためのクラドリビン・レジメン

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2231998T3 (es) 1998-08-10 2005-05-16 Kyorin Pharmaceutical Co., Ltd. Medicina para la esclerosis multiple.
US7534806B2 (en) 2004-12-06 2009-05-19 Avigen, Inc. Method for treating neuropathic pain and associated syndromes

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060093578A1 (en) * 2004-11-04 2006-05-04 Kyorin Pharmaceutical Co., Ltd. Method and composition for treating multiple sclerosis
JP2018080184A (ja) * 2006-05-24 2018-05-24 メルク セローノ ソシエテ アノニム 多発性硬化症を治療するためのクラドリビン・レジメン
JP2010533193A (ja) * 2007-07-11 2010-10-21 メディシノバ，インコーポレーテッド イブジラストを含む進行性神経変性疾患の処置用医薬組成物
JP2012532881A (ja) * 2009-07-10 2012-12-20 サノフィ−アベンティス・ユー・エス・エルエルシー 多発性硬化症を処置するためのテリフルノミドとインターフェロンベータとの組み合わせの使用
JP2017095476A (ja) * 2010-12-07 2017-06-01 テバ ファーマシューティカル インダストリーズ リミティド 多発性硬化症患者において疲労を軽減し、機能状態を改善し、生活の質を改善するための、ラキニモド（ｌａｑｕｉｎｉｍｏｄ）の使用
JP2017132769A (ja) * 2011-02-18 2017-08-03 ザ スクリプス リサーチ インスティテュート ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FOX, ROBERT J. ET AL.: "Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 379, JPN7023003783, 30 August 2018 (2018-08-30), pages 846 - 855, ISSN: 0005333058 *

Also Published As

Publication number Publication date
WO2020076809A1 (en) 2020-04-16
US10946071B2 (en) 2021-03-16
US20200108123A1 (en) 2020-04-09
CA3115269A1 (en) 2020-04-16
EP3863628A1 (en) 2021-08-18
ES2973119T3 (es) 2024-06-18
EP3863628B1 (en) 2023-12-27
CN112770748A (zh) 2021-05-07

Similar Documents

Publication Publication Date Title
US11944607B2 (en) Treatment of progressive neurodegenerative disease with ibudilast
JP2021512921A (ja) 癌療法に対するイブジラストおよび第二の薬剤を使用した方法ならびに投与レジメン
US20230090534A1 (en) Methods of treating glioblastoma multiforme using combination therapy
JP2022504435A (ja) イブジラストとインターフェロン－ベータとの組み合わせ、およびそれを使用する方法
JP7430719B2 (ja) イブジラストを用いて眼疾患／障害または損傷を治療する方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221004

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231003

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231220

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240528